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ABSTRACT

Key, Marc E., M.S., August 1976

Ivlicrobiology

The Immune Response to Malignant IVielanoma in Mice Treated
With Phytohemagglutinin (82 pp.)
Director:

Carl L. Larson

The effects of phytohemagglutinin (PHA) treatment of
mice on the development of specific tumor immunity and the
subsequent effect of this on tumor growth was investigated.
PHA treatment was shown to reduce the survival time of mice
bearing grafted Bl6 melanoma cells and also increased the
development of lung metastases after intravenous tumor
challenge.
To confirm the immunosuppressive nature of PHA, the
cellular and humoral immune responses of mice to other
antigans was studied, PHA reduced the antibody response of
mice to sheep red blood cells and reduced the delayed
hypersensitivity response to Mycobacterium bovis (BCG).
The specific effects of PHA on the immune system were
studied by various in vitro cytotoxicity assays. Macrophage
cytotoxicity tests revealed no differences between
macrophages from tumor-bearing mice treated with PHA and the
macrophages from untreated tumor-bearing mice. Similarly,
assays for the presence of serum blocking factors revealed
no significant differences between tumor-bearing mice
whether or not they were treated with PHA.
Lymphocyte cytotoxicity tests showed that lymphocytes
from tumor-bearing mice treated with PHA were delayed in the
development of specific tumor immunity compared to lymphocytes
from untreated tumor-bearing mice. Lymphocytes from PHAtreated mice were capable also of stimulating tumor cell
proliferation jji vitro.
From these studies a model was proposed to account for
the apparent increased suseptibility of mice to Bl6 tumor
cells after PHA treatment.
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CHAPTER 1
INTRODUCTION
Phytoheniciggulutinin (PHA), an extract from the red
kidney bean, Phaeseolus vulgaris, has been used since the
early 1900s for agglutinating red blood cells.

Landsteiner

(65), who first discovered these hemagglutinating properties,
did much of the early work on this aspect of PHA at the turn
of the century.

It was not, however, until 1959 that the

raitogenicity and blastogenicity of PHA for human lymphocytes
were discovered (74).

This substance could induce the

transformation of small lymphocytes from human peripheral
blood into large lymphoblastoid cells capable of undergoing
mitotic division.

Plant mitogens such as PHA could activate

lymphocytes to undergo blast transformation without prior
antigenic stimulation (?6, 77)•

Lymphocytes from the

umbilical cord blood of newborns are fully capable of
responding to PHA even though they are presumably free from
any prior antigenic exposure.

In contrast, most antigens

stimulate lymphocytes only from previously sensitised donors,
and antigens have no ef1ect on cord blood lymphocytes (76).
This discovery of PHA-induced lymphocyte proliferation had
a great impact on the field of immunology since up until this
time it was believed that lymphocytes were essentially end
cells, incapable of undi^rgoin.": further cell division.
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PHYSICAL,

AKD BIOLOGICAL PROPERTIES GP PHA

Physical and Chemical Characteristics
Rigas and Osgood (86) in 1955 successfully isolated the
hemagglutinin of kidney hearts.

The isolated components

included a simple protein (PHA-P) and a mucoprbtein (PHA-M).
The PHA-P behaved as a homogeneous substance by electrophoresis
over a pH range from 2.0 - 8.0 and had an isoelectric point
of 6.5.

The mucoprotein also migrated as a homogeneous

substance on electrophoretic analysis between pH 5,8 - 8.6
but dissociated into a protein hemagglutinin and an inactive
polysaccharide below pH 5*8.

Both fractions (PHA-P and PHA-M)

could individually agglutinate red blood cells obtained from
various mammalian species.

In 1964 Rigas and Johnson (85)

isolated a protein pytohemagglutinin from Phaeseolus vulgaris
which was homogeneous by ultracentrifugation, electrophoresis,
and column chromatography.

The molecular weight of this

protein was 128,000, and this protein v/as found to possess
both hemagglutinating and mitogenic activities.
Chromatographic separation of a commercially prepared
PHA-P by Weber et al. (105) yielded three separate peaks.
The fraction obtained in the first peak lacked both
hemagglutinating and mitogenic properties..

The material in

the second peak possessed strong mitogenic properties but
lacked hemagglutinating activity, while that in the third
peak contained both a strong hemagglutinin and a weak
mitogen.

Thus, at least tv/o distinct mitogenic factors

separable by their different chromatographic behaviors were
identified.
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has also been shown to cause leukocyte aggulatination.

Hastings et. al (44) observed that when lymphocytes

were stimulated with PHA, cell division occurred primarily
in white blood cell clumps which suggested that theleukoaçglutinin was also responsible for the mitogenic activity.
Kolodney and Hirschhorn (63) found that adsoprtion of PHA
with red blood cells could effectively remove the hemagglutinin
without affecting the leukoagglutinating or mitogenic
activities of the PHA.

However, adsorption with white blood

cells removed all three properties.

These studies indicated

an apparent relationship between the leukoagglutinating and
mitogenic properties of PHA,
Prom these studies it was apparent that PHA was not a
single component but was composed of multiple fractions.
PHA contained a hemagglutinin which could bind not only
erthrocytes but also leukocytes and could be removed by
erythrocyte adsorption without any apparent loss in mitogenic
activity.

This material might be identical to the third

fraction of Weber et al. (IO5) obtained by chromatographic
separation which contained a strong erythroagglutinin and a
weak mitogen.

PHA also contained a second fraction with

both leukoagglutinating and mitogenic properties.

Adsorption

with leukocytes removed both activities while adsorption
with erythrocytes had no effect.

This material might be

identical to the second fraction of Weber and coworkers (IO5)
which was found to contain mitogenic but not hemagglutinating
properties.
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Lymphocyte Surface Receptors for PHA

The possibility that sugar receptor sites might play a
role in the interaction between PHA and lymphocytes was first
investigated by Borberg et. al. (l4).

They showed that

henrmagglutination and leukoagglutination by PHA could be
inhibited by the addition of N-aoetyl-D-galactosamine to
cell cultures.

In a later study Borberg et al.

(15) also

showed t!iat in PHA-stimula ted lymphocyte cultures,
N-acetyl-D-galactosamine could inhibit DM and RNA synthesis,
thus preventing mitosis.

These studies were later confirmed

by Fisher and Mueller (3^) who found that N-acetyl-Dgalactosamine competed with lymphocytes for tlie binding of
and inhibited PHA-induced lymphocyte proliferation.
One explanation for the suppressive effects of N-acetyl-Dgalactosamine on PHA-induced lymphocyte responses, was that
this sugar interfered with the normal binding of PHA to cell
surfaces.

Perhaps N-acetyl-D-galactosamine v/as an integral

portion of the cell wall and the receptor site to which PHA
attached.

Free N-acetyl-D-galactosamine would then compete

with these cellular sites for PHA binding, thus reducing the
availability of PHA to the cell.
Allen (3) has estimated tiiat a single lymphocyte
contained in excess of 6 x 10^ receptor sites for PHA.
Iviitogenic response was greate t when only 3 - lO'/i of tiie total
binding sites were occupied by PHA and v/as reduced when a
larger number of recpetors were bound.
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Apparently tlie interaction of PHA with the cell menbrane
was a necessary step in the stimulation of lymphocytes.
Thymus-dependent Lymphocyte Specificity of PlIA
Despite the fact that PHA was readily bound to both Band T-lyniphocytes (4l), many investifations have shown that
PHA could activate only ï-lymphocytes (6, 37, 75. 76, 79, 96).
Some of the early evidence for the T-cell specificity of PHA
came from the study of patients with congenital immune
deficiency diseases.

Patients with DiGeorge syndrome

(thymic agenesis) were unable to develop cell-mediated
immune responses, although

they were capable of synthesizing

some immunoglubulins (75)•

Lymphocytes from these patients

also failed to respond to PHA which suggested that lymphocytes
mediating cellular i; .mune responses might also be the same
lymphocytes which were responsive to PHA (75).

An analagous

situation was found in congenitally athyraic "nude" mice
whose lymphocytes also failed to respond to PHA jjn vitro (76).
I.iethods for separation of id- and T-cells also have
supported the concept of the T-cell specificity of PHA.
Purified populations of T-lymphocytes responded well to PHA
while purified B-cell populations did not (6, 37» 96).
However, activation of B-cells has been shown to occur in
mixed populations of B- and T-cells.

Piguet and Vassoli (79),

using thyniectouiized, irradiated mice, reconstituted with
genetically distinguishible thymus cells, were able to
differentiate between donor thymus cells and recipient
B-lymphocytes.

They concluded by tiis technique tnat, while
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the early migtogenic response to PllA was due mainly to T-cells,
after 3 days a significant number of B-cells also were
responding.

Goldschneider and Cogen (39) found that yfo of

PHA-transformed lymphocytes gave positive staining reactions
with flourescent-labeled anti Ig which indicated a limited
B-cell responsiveness.

Apparently in mixed lymphocyte

populations, both B- and T-cells could respond to PHA by
undergoing cell division.

In purified populations, however,

only T -cells responded while B-cells did not.

Anderson

et al. (5) and Piguet and Vassoli (79) have concluded that
T-cell mitogens could stimulate T-lymphocytes to release
substances which acted upon B-cells to induce their
proliferation.
Although PhA apparently binds to all lymphocytes, only
a certain percent will Espond by undergoing cell division.
Rubio and Zajicek ( 9 2 ) reported that 70 - 90^ of human lymph
node lymphocytes were transformed after 3 days incubation
with PHA.

Similar results were reported by Bach and

Hirscbhorn (8) for PHA-stimulated cultures of peripheral
blood lymphocytes.

However, Jones (59) felt that these

estimates were falesly elevated due to early cell death and
loss of lymphocytes.

He estimated that PHA stimulated only

11 - 26$ of splenic lymphocyte populations.

Stoiio and

Paul (101) felt that only a subset of T-lymphocytes responded
to PHA,

They described this subset as consisting of

recirculating cells, sensitive to anti-lymphocyte serum, and
relatively resistant to radiation.

In contrast, another

T-cell subset, responsive to tiie T-cell mitogen concanavalin-A,
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was relatively sessile, radiosensitive, and more resistant
to anti-lumphocyte serum.

Some evidence has been presented

recently that this PHA-responsive subset might include a
suppressor T-cell population which could suppress normal
antibody production by B-cells (84).

BLAST TRAl-^SFORMTION OF PHA-STIMULATED SY1..-PHOCYTES

WorpholoKical Changes
The morphological changes observed by light microscopy
in small lymphocytes stimulated with PHA have been described
extensively (22, 71, 87).

The small lymphocyte, prior to

stimulation, contained a large nucleus with condensed
chromatin.

The nucleus was surrounded by only a narrow ring

of slightly basophilic cytoplasm.

V/ithin 24 hr following

the addition of PHA to lymphocyte cultures, nuclear and
cytoplasmic changes were observed.

The cytoplasim volume

increased and became more basophilic, while the nucleus was
found frequently to contain a nucleolus.

Between 24 and 48

hr of culture, typical blast cells appeared which contained
abundant deeply basophilic cytoplasm.

A lighter perinuclear

zone representing Golgi apparatus was present.

The cytoplasm

of these blast cells was pyroninophilic indicated active
RNA synthesis.

Between 4o and 72 hr of culture numerous

mitotic figures were ousorved.
Tonaka et al. (IO3) and Inman and Cooper (5^) studied
the morphology of PHA-stimulated human lymphocytes by
electron microscopy.

After 72 hr of culture in tiie presence
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of PHA, nucleoli were always present, the cytoplasm contained
numerous ribosomes and mitochondria, and Golgi apparatus v/as
well developed.

These changes were interpreted as indicating

increased protein synthesis and mitotic activity in
stimulated cells.
Effects on i\uclelc acid and Protein Synthesis
Several metabolic changes occurred in lymphocytes
undergoing blastogenesis in the presence of PHA.

Through

the use of radiolabeled precursors, the synthesis of DNA,
RNA, and protein has been studied in PHA-stiraulated lympocyte
cultures (23, 68, 73» 94).
The earliest changes observed by Cooper and Robin (23)
in cultures of PHA-stimulated lymphocytes, were a decrease in
total RNA detectable within the first 30 min.

Accelerated

RNA synthesis was apparent after 1 hr. as measured by the
incorporation of tritiated uridine, and continued for 24 hr.
Analysis of the newly formed RM in sucrose gradients
revealed that the synthesis of all classes of RNA was
stimuIsted by PHA (73).
DNA synthesis was observed beginning 24 hr after the
exposure of lymphocyte cultures to PHA as measured by the
incorporation of tritiated thymidine into newly formed
DNA (68).

Tlie percentage of cells synthesizing DNA increased

lo>:ari thill Lcally from approximately 22 hr of incubation to
52 hr of incubation and was followed by significant mitotic
activity.
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Protein synthesis in lymphocyte cultures incubated with
PHA has been studied by Sell and coworkers (94).

They

observed that stimulation of rabbit lymphocytes with PHA
was followed by an increase in protein synthesis.

Both

stimulated and unstimulated lymphocytes incorporated
radioactive lysine into protein during the first 24 hr, but
only PHA-stimulated lymphocytes continued to synthesize
protein during the second 24 hr period.

Turner and Forbes

(l04) cultured hujnan peripheral lymphocytes in the presence
of PHA and used the incorporation of ^^C-amino acids into
protein as an indicator of protein systhesis.

Analysis of

the culture supernatant fluids by startch-gel electrophoresis
and DEAE-cellulose column chromatography showed that a broad
range of proteins containing radioactive material could be
indentified, although the label was strongest in the alpha
2 M-globulins and haptoglobins.

Back and Hirschhorn (7)

found that 5 x 10^ lymphocytes could synthesize approximately
10 ug of protein during a 24 hr incubation period with PHA.
Effects on Cyclic ALP Levels
Another early event in PHA-induced lymphocyte activation,
detectable within the first 20 min, was an increase in
intracellular levels of 3'. 5'-oyclic adenosine monophosphate
(cAmP) (98).

Chloropromazine, an inhiuitor of cAwP synthesis,

blocked the mitogenic stimulation of lymphocytes demonstrating
the importance of cAr.iP (24).

The exact mechanism of action

of cAMP on activation, however, has not been clearly defined.
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THE EFFECT OF PHA ON THE IMviUNE RESPONSE

Antibody Production
Since the discovery that PHA could cause nonspecific
proliferation of lymphocytes in vitro, its possible role in
enhancing the immune response has come under study by many
investigators,

iv.ost of these studies have centered around

the effects of PHA on the humoral immune response.

Despite

numerous reports appearing over the past fev/ ye&rs, no
definitive conclusions on the effects of PHA on antibody
responses have been reached.

Apparently numerous complex

factors determine whether PHA will enhance or inhibit
antibody production to a given antigen.
The administration fo PHA intraperitoneally to rats
24 hr prior to challenge with chick red blood cells caused
a significant reduction in antibody production (30).

In

contrast, if PHA was given 6 hr after antigenic challenge,
antibody production v/as enhanced (30).

PHA has also been

shown to have a similar effect in mice on their antibody
response to sheep red blood cells (18, 29).

Antibody

production was decreased in mice receiving PHA intraper
itoneally prior to sheep red blood cells but was enhanced
when given after the sheep blood cells.

Simultaneous

administration of PHA with sheep red blood cells caused no
significant changes in antibody titer.

Jennings and Oates

(57) reported a reduced primary and secondary immune
response to sheep red blood cells in both rats and mice when
PJIA v/as j iven intraper j toi ieal ] y 1 to 2 days before the
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antigen.

Gengozian and llubner (38) also observed a decreased

antibody response in mice to Salmonella typhosa when PHA was
given 1 day before the antigen.

In contrast, the prior

administration of PHA intravenously enhanced antibody
production in mice to rat red blood cells (36) and in rabbits
to sheep red blood cells (97).
Using tiie Jerne plaque assay technique (3^)> Spreafice
and Lerner (99) demonstrated that the intraperitoneal
injection of PHA simultaneously with, or prior to, the
intraperitoneal injection of sheep red blood cells caused a
significant depression of both the primary and secondary
immune response.

On the other hand, the injection of PHA

after the antigen had no effect on the plaque forming cell
response.

However, the direct addition of PHA to a Jerne

plaque assay after 48 hr of culturing sensitised mouse
spleen cells in the presence of sheep red blood cells,
increased the plaque forming cell response (84).
From these studies it is apparent tiiat both the route
of administration of PHA and timing of injection in relation
to the antigen were important factors in determining whether
antibody production was enhanced or decreased.

Other factors

which might influence the antibody response to PHA and must
be considered were the type of animal under investigation,
the amount of PHA injected, and the amount of antigen given.
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The Effect of PHA on Gell-l.iediated Immune Responses
Lyraphokine ProductionLymphocyte cultures treated in vitro with PHA have been
shown to produce numerous lymphokines similar to those
produced by sensitzed T-lymphocytes in response to specific
antigen.

Jeffes and Granger (55) have shown that PHA-

stimulated lymphocytes released lymphotoxin, proliferation
inhibition factor, and cloning inhibition factor.

The studies

of many investigators have documented the destructive effects
of PlIA-stimulated lymphocytes on target cells (13» 40, 51-53) •
These lymphocytes were either directly cytotoxic or released
cytotoxic substances which could kill a large variety of
both syngeneic or allogeneic target tumor cells.

Other PHA-

induces lymphokines which have been reported include
macrophage migration inhibition factor (64), skin reactive
factor (78), and interferon (35).
Delayed HypersensitivityThe relase of lympnokines by PHA-stimulated lymphocytes
is in many ways similar to the lymphocyte response triggered
by specific antigen.

Because of this apparent similarity

the effect of PHA on cell-mediated immune responses has been
investigated closely, Schrek and Stefani (93) found that the
intradermal injection of PHA in human volunteers produced an
inflai matory response with maximal induration at 24 hr similar
to a delayed hypersensitivity reaction.

Otner investigators

also have observed a similar response to the intradermal
i n j i; c t i o11 o f PHA ( 1, 67 ).
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Apparently the localized injection of PilA could elicit
an inflammatory response at the site of injection.

On the

other hand, the injection of PHA intraperitoneally or
intravenously might be expected to trigger a systemic
stimulation of lymphocytes and release of lymphokines, thus
rendering; tnem less responsive to a localized antigenic
challenge and reducing their ability to produce a local
inflammatory response.
Tne systemic treatment of mice, rats, and rabbits with
PHA has, in fact, been shown to depress cell-mediated
immune responses.

Stevens and Willoughby (lOO) have invest

igated the effect of PHA on the expression of delayed
hypersensitivity in rats to pertussis vaccine.

PHA was

administered intravenously prior to the injection of
pertussis vaccine and then daily for 12 days dollovving the
vaccine injection.

A decreased inflammatory reaction,

following antigenic challenge on day 12, was observed.

If

PHi'i was given only 24 hr prior to the challenging dose, no
reduction in the infla/iinatory response resulted.
Graft Survivaljvlarkley et al. (70) administered PHA intraperitoneally
into rabbits beginning 2 days before the placeiuent of a skin
allograft in the rabbit's ear and continuing daily until the
graft was rejected.

PHA increased the survival time of the

allograft from an average of 6.9 days to 15.2 days.

More

receiving daily injections of PHA for 3 consecutive days
followed by allogeneic skin grafting on day 4, retained the
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skin ,«;r£ft longer than untreated controls (102).

On the

other hand, a single injection of PHA either 24 hr before or
after the time of skin grafting did not increase graft
survival time in mice (60).
Effect of PHa on Tumor GrowthRobinson and Wekori (90) investigated the eii'ect of PHA
treatment on ascites tumor cell survival in mice.

PHA was

administered to mice intraperitoneally at various time
intervals prior to, or subsequent to, the intraperitoneal
injection of ascites tumors.

Seven days after the injection

of tumor cells, the peritoneal cavity was washed, and the
packed cell volume was determined.

Robinson and Mekori

found a reduction in packed tumor cell volume compared to
control mice when PîiA was administered 72 hr prior to tumor
cell implantation.

However, treatment with PHA 120 hr before

tumor implantation resulted in an increased tumor volume on
day 7.

Robinson and Iiekori suggested that PHA-"modified"

lymphocytes were able to destroy tumor cells _in vivo.

The

effect of PHA apparently was a transient one and might, in
fact, act to reduce lymphocyte cytotoxicity in the long run
as indicated by the increased tumor cell volume when PHA was
given 120 hr prior to tumor cell injection.

However, based

upon these results, itie tentative use of PHA in cancer
patients was tried, and some temporary improvement was
reported (88, 89).

Mobley et al. (72) also showed a slight

increased survival time in PHA-treated mice given Erlich
ascites tumor cells.

i..ice given tumor cells intraperitoneally
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followed by treatment with PHA on days 1, 3, and 5i had a
mean survival time of 10.6 days, while control mice had a
mean survival time of less than 8 days.

Although this

difference was not highly significant (p> 0.05,^ 0.1),
perhaps PHA could exert some early tumor-inhibiting effects.
In contrast, neit'.ier Datta et al. (25) nor Hubio and
Unsgaard (91) could find any protective effects of PHA on
ascites tumor growth in mice.

SUMMARY
The plant lectin, phytohagglutinin, isolated from beans
of the genus Phaeseolus. has been shown to produce blastogenic
and mitogenic changes in lymphocyte populations.
were also induced to release various lymphokines.

Lymphocytes
Because

these effects were in many respects similar to the effect of
specific antigen on sensitized lymphocytes, the effects of
PHA on immune res onses liave been studied by many investigators.
In general, it has been found that PHA suppressed both humoral
and cell-mediated im, iune responses, although in some cases
PHA was found to enhance antibody formation.
The effect of PHA on tumor immunity was not clear.

The

in vitro treatment of lymphocytes with PHA could lead to the
development of cytotoxic lymphocytes capable of destroying
tumor target cells.

Although the early effects of PHA might

be to modify lympliocytes to kill tumor cells, as was believed
by Robinson and Mekori (90), it might also act to retard the
development of specific tumor immunity, thus in the long run
promo tin;'" tumor ;,x-ov/th.
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STATEKiENT OF PURPOSE
Preliminary studies have been performed to determine
what effect FHA treatment would have on the survival time of
mice bearing grafted malignant melanoma.

The results of

these studies have shovm that survival time was shortened in
mice treated with Plià and tumor cells, indicating a possible
PHA-induced immunosuppression.

The purpose of the present

study was to investigate the effects of PHA on the immune
system of mice and to determine why pretreatment of mice
with PHA caused an apparent increased suseptibility to
malignant melanoma as indicated by their shortened survival
time.

Three different components of the immune system,

lymphocytes, macrophages, and serum factors, were studied
to determine whether one or more of these components may be,
in part, responsible for this apparent increased
suseptibility.

CHAPTER 2

MATERIALS AND METHODS
MICE
C57 Black mice, 2 to 5 months old, were obtained from
the Rocky fountain Laboratory in Hamilton, Montana.

Upon

arrival the mice were held for a 2 week observation period
and supplied with water containing 300 ug/ml tetracycline.
They were housed 8-11 per cage and allowed food and water
ad libitum during the experiments.

REAGENTS AND TISSUE CULTURE PREPARATIONS

Minimum Essential Medium CviEM)
Commercially preparaed powdered MEM (GIBCO, Santa Clara,
CA.) containing Earle's salts, L-glutamine, and nonessential
amino acids, was reconstituted with triple distilled water
and supplemented with Penicillin G (lOO U/ral) and
Streptomycin sulfate (100 ugV /nl).

To increase the buffering

capacity of the medium, NaHCO^ and N-2-hydroxyethylpiperazineN-2-ethansulfonic acid (HEPES, Sigma Co., St. Louis, MO.)
were added to concentrations of 1.0 mg/ml and 3*57 mg/ml
respectively, and tlie pH was adjusted to 7.35 witli IN NaOJi.
The medium was sterilized by filtration t(trough a 0.22 un
pore size Millipore filter (i.illipore, Bedford, liA.) and
stored at 4^C.

Heat-inactivated fetal calf serum (GIBCO)

was added to yield a final concentration of 10>i (I.iEM + PCS).
Thio n:e(i;iuin wr-.s used i n all tents foi' the _in v i. tro f'jrowth
of tumor celifj.
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Phosphate Buffered Saline
Dulbecco's phosphate buffered saline (DPB.S), pK 7 . 2 ,
was prepared according to the method of Dulbecco and Vogt (27)
and used to harvest and wash spleen cells and peritoneal
exudate cells.

Calcium and magnesium free DPB3 (Pd) was used

to wash, prior to harvesting, tumor cell monolayers grown
in vitro.

Trypsin
Crystalline porcine trypsin (Sigma) was dissolved in
HEPES buffered saline (95) to yield a final concentration of
either 0.05/» (wt/vol) or 0.25^ (wt/vol).

The pH was adjusted

to 7.35 with IN NaOH, and phenol red (10 mg/l) was added as
a pH indicator.

The trypsin preparations were sterilized by

filtration and frozen until used.

The 0.05% trypsin was used

to remove tumor cells from the bottoms of tissue culture
flasks, while the 0.25/^ trypsin was used to digest solid
tumors into single cell suspensions.
Trypan rlue
Trypan blue (GIBGO) was used to determine the viability
of all cell preparations.

One part of 0.4^ trypan blue was

added to 4 parts of the cell suspension and incubated for 5
min at room temperature.

A portion of this mixture was

added to a Spencer 'Mirigiit Line" hemocytometer (American
Optical, Buffalo, NY.), and cell counts were performed.
Cells capable of excluding the trypan blue dye were
considered viable, and the percentage of visble to stained
cells was determineci for al] eel] suspensions.
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F i c o11-K y pa q u e
Lyn.phocyte-rich cell suspensions were prepared from
mouse spleens by the removal of erythrocytes, granulocytes,
and macrophages, by centrifugation in a Ficoll-Hypaque
density gradient.

Ficoll (Pharmacia, Uppsale, Sweden) was

autoclaved a s a 9 ^ solution (v\ft/vol) a n d adjusted to pH 7 . 2 .
Sterile 32.(v/t/vol) sodium riietrizoate (Hypaque) (Nygaard,
Oslo, Norway) v/as prepared, and 24 parts of Ficoll were
added to 10 parts of Hypaque.

The Ficoll-Hypaque preparation

was stored at 4°G and protected from light.

Tris-buffered Ammonium Chloride
Tris-buffered ammonium chloride, pH 7.65, was prepared
by mixing 1 part of 0.17M tris buffer (Sigma) with 9 parts
of 0.(33/'' (v/t/vol) ammonium chloride.

This preparation was

prepared immediately before use and used to lyse erythrocytes
contaminating the spleen cell preparations.
Phytoliei agglutinin
A commercially prepared, dessicated, PhytonemagglutininP (PHA-P), purchased from Difco Laboratories (Detroit, MI.)
was dissolved to the desired concentration in DPBS
immediately before use.

Mice were injected intraperitoneally

with 0.2 ml of the PHA-P solution.

BOG Vaccine
BCG vaccine, maintained in stock at the Stella Duncan
Institute, Missoula, Montana, was prepared from Mycobacterium
bovis (BCG), Paris strain, by growth in Uubos broth (26).
Cells were w/isited and resuspe ,ded in Dubos brotii to an
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optical density reading of 200 (K-200) on a Klett-Summerson
photoelectric colorimeter equipped with a blue filter
(Klett-Summerson ^42, 400-465 nm).

This stock suspension

was distributed in vials and stored at -70 C.

Vials were

thawed under warm tap water, diluted with an equal volume of
Dubos broth, and 0,2 ml were injected intraperitoneally into
mice.

This dose contained between 5 x 10^ and 10 x 10?

colony-forming units of BOG.

BOG.Protoplasm
BCG protoplasm was maintained in stock at the Stella
Duncan Institute and had been prepared by resuspending twice
washed BCG in distilled water to a concentration of 10 to 15
gm (wet weight) per 100 ml.

Cells were ruptured in a Sorvall-

Ribi cell fractionator at 45,000 psi, and the effluent was
centrifuged (27.000Xg) for 1 hr to remove cellular debris.
The supernatant fluid, termed protoplasm, was lypholized and
stored at -20^0.

HANDLING OF TbWOR CELLS
Tumor Cells
I alignany melanoma (Bl6) tumor cells, obtained from the
Jackson Laboratory, Bar Harbor, Maine, were used throughout
these studies.

This tumor arose spontaneously in C57B1/6J

mice as a tumor at the base of the ear (42).
Preparation of Tumor Cell Pool
Approximately 1 x 10-5 tumor cells were injected
suhout;ineou.<.;ly into Uiu nuchal area of /uico.

When tae tumor
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growth had progressed to approximately 10 mm in diameter, the
tumor was removed to start a uniform tumor cell stock.

The

surface area over the tumor was shaved and disinfected with
IQfo ethanol, and the skin was dissected on three sides of the
tumor to form a skin flap.

The flap of skin with the

attached tumor was reflected from the underlying surface,
and the tumor was removed and minced into small fragments of
approximately 1 mm in diameter.

The tumor fragments were

washed three times with Pd and them digested for five
minutes with 0.25/^ trypin.

The single cell suspension

obtained by trypsinization v/as filtered through sterile
cotton gauze into a conical centrifuge tube containing
MEiu + PCS.

The trypsinization procedure was repeated three

times, and the single cell sustensions were polled and
centrifuged for 5 min at 250Xg and 4°C.

The supernatant

fluid was discarded, and the cell pellet was resuspended in

r.iEM + PCS.

Tissue culture flasks (Falcon Products, Oxnard,

CA.) were seeded at a density of 3 x 10

h

?

tumor cells-cm^

surface area and grown for 72 hr in a humid atmosphere of
95/^ air and 5/^ COg at 37^0.

After four passages of the

tumor cells jji vitro. tumor cell monolayers were rinsed
three times with Pd, and the cells were digested from the
bottoms of the flasks with 0.0S% trypsin.

Tumor cells were

washed once with kEiVi + PCS and resuspended to a density of
4 X 10^ viable cells/ml in iviiiivi + PCS containing 10)u (vol/vol)
dimethyl sulfoxide (J.T. Baker, Phillipsburg, NJ.) added as
a cryopreservative.

One ml amounts of the cell suspension

were sealed in glass ampules and checked for leads by
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immersion in a O.O^'/ô methylene blue solution for 30 min at
4"G.

Ar.rpules showing no entry of the dye were frozen in

95^5 ethanol at -70*0 for 2 hr prior to transfer to liquid
nitrogen.

Tumor cell stocks were stored frozen at -196*0

in liquid nitrogen until needed.
Passage of Tumor Galls
All tumor cells used for _in vitro cytotoxicity tests
and for in vivo tumor challenge experiments were obtained
from the same tumor pool stored in liquid nitrogen.

To

prepare the tumor cells an ampule was removed from the liquid
nitrogen and thawed under warm tap water.

The cell suspension

was removed from the ampule, washed once in iviEM + PCS, and
transferred to a 75 cm

2

tissue culture flask.

After 72 hr

of incubation, tumor cells were harvested from the flasks as
described and resuspended to the diesired concentration in
IwEW +PC3 for cytotoxicity assays or iviEf.'i without fetal calf
serum for _in vivo challenge.

Tumor cells processed in this

manner were of consistantly high viability {>95%) as
determined by trypan blue exclusion.

EFFEGTS OF PHA ON IMMUNE RESPONSES

Antibody Production to Sheep Red blood Cells
ï'o determine the effects of PUA treatment on the ability
of mice to troduce antibodies to sheep red blood cells, mice
were injected intraperitorieally with 400 ug of PHA either
?Ji- hr before or after the injection of sheep red blood cells

also in li'aper L tonea'l l .
.,y

Approxlma 11.1 j 2 . If - ..I'ljep red
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blood cells were Injected per mouse, and 6 days later the
mice were bled from the brachial artery.

The serum was

separated from the cells, and antisheep red blood cell
hemagglutinin titers were determined on the complement
inactivated serum.

Titrations were performed in micro-titer

plates, each well containing 0.25 ml oi' titrated serum,
0.25 ml of DPiiS, and 0.25 ml of a ifo sheep red blood cell
suspension in DPBS.

Tlie plates were incubated for 2 hr at

room temperature, and the titer was determined as the
reciprocal of the highest serum dilution showing agglutination.
Delayed-llypersensitivity Response to BCG Protoplasm
l.iice were immunized on day 14 with BCG vaccine and then
treated at various time intervals with 400 ug of PHA
intraperitoneally.

On day zero 20 ug of BCG protoplasm in

a 0.03 ml volume were injected into the right hind footpad.
The left hind footpad was injected with O .O3 ml of DPBS
only.

The footpad thickness was measured 24 hr later with a

Schnell tester ( U.C. Kroplin, GMBH, Postfach, West Germany),
and the thickness of the control foot was subtracted from
the thickness of the BGG challenged foot to determine the
specific inflammation due to BCG.
This experiment showed a reduction in the delayed
hypersensitivity response to BGG in inice pretreated with
PM.

To determine whether tnc effect of PHA was upon

lymphocytes or macrophages, lymphocyte transfer experiments
were performed.

Spleen cells were prepared by mincing whole

snlé'.nu through //60 uiet:\i wire t-jcreeas into plastic petri
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dishes containing 5 ml

+ PCS per spleen.

The dishes were

incubated for 45 rnin in a humid atmosphere of 95% air and 5^

CO2 at 37^*0 to remove most adherent cells.

White blood cell

counts were performed, and the suspenstion was adjusted to
2.5 X 10^ viable white blood cells per ml.

Spleen cells from

mice immunized with BCG and pretreated with PllA were injected
intraperitoneally into normal, unimmunized, syngeneic
recipients.

A total of 5 x 10^ cells in a 0.2 ml volume

were injected per mouse.

Recipient mice were challenged 24

hr later in the footpad with BCG protoplasm.

Since recipient

mice contained normal macrophages but only sensitized donor
lymphocytes previously exposed to PHA, failure to mount a
delayed reaction to BCG protoplasm would indicate a failure
of- the sensitized lymphocytes to respons to the antigen.
The reverse experiment was also performed.

Lymphocytes

from BCG sensitized mice were injected into unimmunized
recipients which had been pretreated with PHA.

Failure to

mount a delayed reaction in this case would indie; te that
the primary action of PHA had been upon tlie recipient's
macrophages.

IN VIVO TUMOR CHALLENGE EXPERIMENTS
Survival Time
liice were treated with a single injection of PHA either
24 hr before or after the injection of tumor cells.
concentration of PHA was varied between groups.

The

Tumor cells

were prepared in l-iJil.'i, and a total of 15O cells in a 0.2 ml
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volume were injected intraperitoneally.

Lice were observed

daily, and the day of death was recorded.
Mice were treated also with multiple injections of PHA
at various time intervals both before and after the injection
of 150 tumor cells, and the day of death was recorded.
LunK Tumors
Mice were treated with a single intraperitoneal injection
of PliA, the concentration varied from group to group, either
24 hr prior to, or subsequent to, the injection of 1 x 10^
tumor cells into the tail vein.

After 21 days the mice were

killed, and the lungs were removed and immersed in Plutzniks
fixative (80) for 24 hr.

Plutzniks solution consisted of

91 parts of 70fo ethanol, 4.5 parts formalin, and 4.5 parts
acetic acid.

After 24 hr the lungs were removed from the

fixative, and the number of surface, lung tumors visible with
3OX magnification were counted.

IN VITRO CYTOTOXICITY ASSAYS
iviice were divided into 4 groups of I8 animals each.
Group 1 served as controls and received no treatment.

Groups

2 and 3 were injected intraperitoneally with 250 tumor cells
on day zero, while r :roupa 3 and 4 were injected intraperiton
eally with 400 ug PxIA on day -1.

At 5 or ? day intervals 3

mice from each group were killed, and their cells were
pooled and tested for in vitro cytotoxicity toward tumor
cells.
obtained

Cells and serum for all cytotoxicity tests were
L 'ro ;ii

tiiese ;"rou,,s of mice.
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liacroT)hap;e Cytotoxicity Assay
Peritoneal exudate cells were harvested from PHA-treated
mice and untreated mice at various time intervals after the
intraperitoneal injection of 250 tumor cells.

Mice were

killed by cervical dislocation, immersed in a dilute
amphylsolution, and carefully skinned without rupturing the
peritoneal cavity.

Four ml of cold DPBS were injected into

the,peritoneal cavity with a 27ga needle.

The cavity was

massaged gently and then swabbed 70^ ethanol.

Peritoneal fluid

was withdrawn into a syringe with an l8ga needle and added
to siliconized conical centrifuge tubes kept on ice.

The

peritoneal fluid from 3 mice was pooled, and the tubes were
centrifuged at ^^^xg for 5 min at 4°C.

The cell pellets were
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resuspended in InEM + PCS to a concentration of 1 x 10 viable
cells/ml,

A 0.1 ml portion, containing 10^ cells, was

spotted in the center of a 24 mm plastic coverslip (Lux tflv.
Thousand Oaks, CA.) contained in a 35 mm petri dish (Falcon,
Oxnard, CA.)

and incubated in a humidified container for

45 min in an atmosphere of 5/^ COg and 95'/® air.

Following

incubation, the coverslips were rinsed three times with
streams of 2 ml cold DPBS dispensed from a Cornwall continuous
pipetting apparatus to remove all nonadherent cells.

The

cell;j remaining after washing formed a spot of approximately
1 cm in dlcUneter and were considered to be predominantly
macrophages.

A total of 3-0 x 10^ tumor cells in a 3 ml

volume were added to tiie petri dishes and incubated at 37^0
for 72 hr in a humid atmosphere of 5% CO

and 95;-5 air.

Expended medium v/as replaced with fresh i.iedium after 24 and
48 hr of incubation.

Following incubation, the coverslips

were removed from their dishes, rinsed three times in DPBS,
and fixed for 5 min with methanol.

The coverslips were

then stained for 60 sec with a 0.1^^ solution of crystal
violet, rinsed, and dried.

The stained coverslips were

Mounted on microscope slides and observed by lig^it microscopy
under h if:h power (450X).

The number of tumor cells in 10

lii.'ih power fields (hpf) were counted, and each assay was
performed in duplicate so tliat a total of 20 high power
fields were observed.

The average number of tumor cells

per hi^h power field was determined, and the percent
cytotoxicity was calculated by comparing test cultures to

normal cultures by the following formula:
X 100 = % cytotoxicity
K = Mean number of tumor cells/hpf in normal cultures
T = Wean number of tumor cells/hpf in test cultures

l-.acrophages from mice immunized with BCG have been
shown to be cytotoxic for Bl6 tumor cells in macrophage
cytotoxicity tests (43).

Macrophages obtained from mice

vaccinated 14 days previously with BCG were used as positive
controls in all macropha e cytotoxicity assays.

These

macro)hage-rich cell preparations continually manifested
between 55 - 70/) cytotoxicity in all tests.
The effect of in vitro PHA treatment on BCG-sensitized
mice was investigated also to determine whether PHA could
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alter the response ox their activated macrophages in
macrophage cytotoxicity assays.
Lymphocyte Cytotoxicity Assays
ïris-buf fered Ammoniuiri chloride Separation of Spleen CellsI'iice were killed by cervical dislocation, and the
spleens were ascey.tioally removed to s ; erile petri dishes
containing r/60 mesh wire screens.

Tliree spleens were pooled

and minced through the screens into 15 ml of cold UPBS.

The

cell suspensions were transferred to conical centrifuge
tubes on ice, and the large tissue fragments were allowed to
sediment for 10 min.

Five ml of the upper single cell

suspension were removed to a second centrifuge tube, and the
remainder was saved for Ficoll-itypaque separation.

Tubes

were centrifuged at 4^C for 10 rain at 400Xg, and tne cell
pellet was resuspended in 10 ml of tris-buffered ammonium
chloride.

After 10 min incubation to lyse contaminating

erythrocytes, the cells were centrifuged, and the supernatant
fluid was discarded.

The cell pellet was washed three times

in DPdS by centrifugation for 5 win at 400Xg.

Following the

final wash the cell pellet was resuspended in IvlEi'.i + PCS to
yield a final concentration of 4 x 10^ viable cells per ml.
Viability as determined by trypan blue exceeded 80/».

Ficoll-Hypaque Separation of LynphocytesSix ml of the spleen cell suspension previously
prepared were layered over 3 fnl. of Ficoll-Hypaque and
centrifugcd for 20 lain (400Xg, 4^0).

The lymphocyte-rich

intarfcice was removed to a second centriftube, diluted
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v/itîi an equal volume of DPBS, centrifuged, and the cells were
washed three times.

After the final wash the cells were

resuspended in IviKlvi + PCS to a final concentration of 4 x 10^
viable cells per ml.

Viability as determined by the exclusion

of trypan blue exceeded 955^»
Performance of Assay1licrotest plates (Falcon, ^3034, Oxnard, CA.) were seeded
p
with ?, X 10 tumor cells per well in a 10 ul volume 24 hr
prior to testing.

At the time of testing, 10 ul of the

appropriate spleen cell suspension were added to each well to
give 4 X 10^^ cells per well or a ratio of effector cells to
target cells of 200:1.

Plates were incubated in a humid

atmosphere of 95/^ air and 5/o COp at 37for 48 hr.

Plates

were then rinsed three times in DPiiS, and the cells were
finxed in methanol and stained for 1 min with 0.1# crystal
violet.

The number of tumor colonies present in the wells

were determined microscopically.

Replicates of 10 wells were

performed for each test group, and the average number of
tumor colonies present per well was determined.

The percent

cytotoxicity was determined as follows:

X 100 = io cytotoxicity

N = I'lean number of tumor colonies/well cultured with normal
lymphocytes
T = I'lean number of tumor colonies/well cultured with test
lymphocytes
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Determination of Serum Blocking Factors
Blood was collected at various time intervals from the
brachial artery of ether-anesthetized mice.

Serum v/as

separated from the clotted blood and frozen until tested.
Lymphocytes from mice injected intraperitoneally with 250
tumor cells, 18 cells days previously, were prepared by the
Ficoll-iiypaque method and used as effector cells because of
their known cytotoxicity (see Figure 2).

Microtest wells were

seeded with 2x10' tumor cells 24 hr prior to assay.

At the

time of testing, the medium was discarded from the plates,
and 5 ul of test serum were added to the appropriate wells.
Plates were then incubated with the serum for 2 hr.

Ten ul

of lymphocytes (4 x 10^/ml) were added to each well, and the
plates were incubated and processed as previously described.
Percent cytotoxicity was calculated by the following formula;

X 100 = fo cytotoxicity

N = Mean number of tumor colonies/well cultured v/ith normal
serum
T = i.lean number of tumor colonies/well cultured with test
serum
Cell Counts and Characterization of Cell Types
All tumor cell preparations were counted microscopically
v/ith a Spencer lieinocytonieter, and appropriate dilutions were
prepared.

Suspensions of peritoneal exudate cells and

spleen cells were counted electronically on a Model %
Coulter Counter (Coulter Electronics, Hialeah, FA.).
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To determine the various cell types comprising the
spleen cell preparations, normal spleen cells were processed
in the usual manner, and the cell pellets were resuspended
in twice their volume of ZZfo bovinealbumin (Ortho Diagnostic,
Raretan, NJ.).

Thin smears were made on microscope slides

and stained with Wright's stain.

The slides were examined

microscopically, and cells were categorized according to
morphology.

Cell counts were made before and after the

removal of the adherent cell population.

By these methods it

v/as determined that spleen cells prepared in tris-buffered
ammonium chloride were composed of approximately 60'/o
lymphocytes and 40^ macrophages (see Table 1).
will be referred to as spleen cell preparations.

These cells
Spleen cells

prepared by centrifugation on Ficoll-Hypaque were composed
of approximately 90/o lymphocytes and lO'ji macrophages and will
be referred to as lymphocyte preparations.

Cytotoxicity

assays using adherent cells and assays using Ficoll-Hypaque
prepared lymphocytes were performed to measure the cytotoxicity
of macropliagea and lyi.iphucytes respectively.

However, to

test for the possibility of synergistic effects between
mixed cell populations, a spleen cell preparation (ammonium
chloride) containing both lymphocytes and macrophages was
also tested.

The Effects of Contaminating kacropha/^es on Lymphocyte
Cytotoxicity Assays
To determine the effects, if any, of contaminating
macrophages on lymphocyte cytotoxicity tests, 20 ul of each
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lymphocyte cell suspension were added to I.icrotest v/ells,
allowed to adhere for 45 min, and then rinsed vigorously
4
three times leaving only adherent cells. Since 8 x 10 cells
were added of which approximately lOfo were macrophages, this
would leave o x 10^ macrophages remaining per well or

lymphocyte cytotoxicity test.

Two hundred tuiiior cells were

added per well, and the plates were incubated for 48 hr,
stained, and processed as described.

STATISTICAL ANALYSIS
The Mann-Whitney U test (69) was used to determine
Whether two independent groups had been drawn from different
copulations.

To apply the U test, scores from tv/o independent

groups were ranked in order of increasing size.

The value

of U (the statistic used in this test) was determined by the
number of times the scores in the first group with n^ cases
overlapped tuc

:

-i-ds in tlie second group with n^ cases.

To compute ]] the rank of 1 was assigned to the lowest score
in the combined (n. + n ) group of scores, the rank 2 was
^
2
assigned to the next lowest score, etc. The sum of the ranks
for each group was determined.
= Sum of the ranks assi.-ned to the group with n, cases
Rp - 3uiA 01 the ranks assigned to the group with rip cases
To compute U:
"t" l)

u = n^ng +
—— 2
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Table 1
Characterization of Cell Types
In Normal Spleen Cell Preparations

Ficoll-Hypaque Separation
A.

Group

# adherent

Cell Counts X 10
before
after
adhering adhering

1.
2.
3.

8.4
9.6
8.8

7.7
8.6
7.9
Average

B,

PI.iN's

Avera:;,e

II.

8.3#
10.4#
10.5#

91.7#
89.6#
89.9#

9.7#

90.3#

Differential
Macrophages

Group

1.
2.
3.

# nonadherent

Lymphocytes

4
1
1

8
7

88
92
94

2.0

6.7

91.3

Ammonium Chloride Separation
A.

Group

Cell Counts X 10^
before
after
adhering adhering

1.
2.
3.

B.

3.1
3.2
2.9

Group
Pl:M • s
1.

2.
3.
Average

% adherent

% nonadherent

1.9
1.8
1.7

39.4#
43.2#
40.1#

60.6#
56.8#
59.9#

Average

40.9#

59.1#

Differential
iacrophages

Lymphocytes

0
2
4

40
33

60
65
64

2.0

35-0

63.0
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Tiie above equation which yielded the smallest value for U
was used to determine the significance of the difference
between the test groups.

The level .of significance was read

from the appropriate table for the computed U value.
Defferences between groups where p<0.05 were considered
sir:nif ican i..

CHAPTER 3
RESULTS
THE EFFECT OF PJIA TREATMENT ON THE REPONSE OF
MICE TO IN VIVO TUMOR CHALLENGE

Lunp" Metastases
To determine the effect of PHi treatment on the number
of lun^- metastases developing after intravenous tumor cell
challenge, mice were divided into 9 groups of o mice each.
Animals in group 1, serving as controls, received no PHA
treatment.

Mice in groups 2 - 5 received different amounts

of PHA injected intaperitoneally 24 hr prior to tumor cell
challenge, while those in groups 6 - 9 received PHA 24 hr
after tumor challenge.

All animals received 1 x 10^ tumor

cells intravenously at time zero.

Mice were autopsied on

day 21, and the number of surface lung tumors were counted.
The effect of PHA treatment on the development of lung
metastases is summarized in Table 2.

These results show

that the treatment of mice with PHA either before or after
tumor cell challenge could increase significantly the
development of lung tumors.

PHA given after tumor cell

challenge appeared more effective in this respect.
Survival Time
The effect of PiIA treatment on the survival time of
tumor-bearing mice was also treated.

Nine groups of mice,

8 animals per group, were injected intraperitoneally at
tiiiie z e r o w i t h 15-0 t u m o r colli,:.

Animuls i n ;rou,is 2 - 5

were injected \,i Lli various concentrzit i ,inu oi' I'hA 24 In- befoi e
35
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I'iiBLii 2
The Effect of PllA on Lung Metastases in Lice
Challenged iv with 1 X 10-5
Bl6 Tumor Cells
Group

Treatment

I.iice/group

Lung tumors/mouse
(mean8+ SD)

1.

none

8

4.9 ± 2.6

2.

400ug PHA, d-1

8

9.5 ± 4.7

.041

3.

ZOOug PHA, d-1

8

10.G + 7.2

.041

4.

S On(Z 1 i A I d — 1

8

6.6 ^ 4.5

.253

5.

5u"' fiiA, d-1

8

5.0 + 2.1

.439

6.

40Oug PHA, d+1

8

1 0 .1 + 3 . 6

.041

7.

200ug PHA, d+1

8

11.0 + 6.9

.032

8.

50ug iilA, d+1

15.0 + ^.8

.001

.

5'-';: fi'A, d+1

7.5 + 2.6

.003

a.

Level of significance of difference between test group' and
control gourp 1
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tumor cell challeiu-e, while tnose in croups 6 - 9 were
injected with PHA 24 hr after tumor challenge.

The results

of PHA treatment on survival times are summarized in Table 3
and show tnat treatment with PHA caused a slight decrease in
survival time of tumor-bearinj; laice.
To de termine './hetiier multiple i.ijections of PliA would
be more effective than a single injection in decreasing
survival time in tumor-bearing mice, animals were treated
with three injections of PHA.

A single injection was given

5 days and 1 day before tumor cell challenge, and 4 days after
tumor ciiallenge.
group to goup.

The concentration of PHA v/as varied from
All mice received 150 tumor cells

intraperitoneally on day zero.

The results of multiple PHA

injections on survival times, summarized in Table 4, show
t lat multiple injections of PHA significantly reduced survival
time of tumor-bearing mice at the higher doses tested.

THE EFFECTS OP PHA

VITRO CYTOTOXICITY ASSAYS

Seventy two mice wei-e divided into 4 groups of iB mice
eacii.

nice in group 1, serving as controls, received no

treatment.

Animals in groups 2 and 3 received an intra

peritoneal injection of 250 tumor cells on day zero.

Tliis

dose of tumor cells will l^ill normal mice in 40 - 50 days.
Lice in groups 3 and 4 received 400 ug of PHA intraperitoneally
on day -1.

Tliree mice from each group were Killed at 5 or 7

day intervals and their cells rmd serum pooled for
cytotoxicity.
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TABI,E 3
T;ie Effect of PiiA on the Survival Time of Mice
Challenged ip with I .5 X 10
B1.6 Tumor Cells
Group

Treatment

Nice/group

Survival Time (days)
(mean + SD)

p®-

1.

none

8

51.6 + 16.7

——— —

2.

400ug PliA, d-1

8

42.2 +

8.0

.287

3.

200ug PHA, d-1

8

39.2 +

6.7

.221

k.

50ug PHA, d-1

8

43.0 +

7.2

.368

5.

PHA, d -1

8

42.7 + 11.5

.253

6.

400ug PHA, d+1

8

45.0 +

5.3

.439

7.

200ug PHA, d+l

8

51.9 +

9.4

B.

PHA, d+1

8

46.8 +

5.7

9.

PHA, d +l

8

48.9 + 12.1

a.

.399

Level of significance of difference between test group and
control group 1
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TfiBLE 4
The Effect of Multiple PMA Treatment on the„Survival Time
of r .iice Challenged ip with I.5 X 10
BI6 Tumor Cells
Group

Treatment

Mice/group

Survival Time
(days)
(mean + SD)

1.

none

6

50.1 + 12.1

2.

400ug PHA, d-•5, -1,+4

8

36.4 +

3.6

.010

3.

200ug PHA, d-•5, -1 »+4

8

34.5 ±

3.4

.001

4.

50ug PHA, d-•5, -1 ,+4

8

33.6 +

2.6

.001

5.

PHA, d-•5, -l,+4

8

42.7 ± 10.2

.097

Level of significance of difference between test group and
control group 1
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Idacropha/':e Cytotoxicity Tests
Peritoneal exudate cells were pooled from 3 Jnice in each
group for macrophage cytotoxicity testing.

Mice in group 5

served as positive controls and were inmiunized with BCG 14
dyas prior to the performance of each assay,

i-iacrophage-rich

cell preparations feom mice immunized in this manner consis
tently showed a high degree of cytotoxicity toward tumor cells.
The results of the macrophage cytotoxicity assay are
summarized in Table and Figure 1.

These data show that

macrophage-rich cell preparations from tumor-bearing mice were
cytotoxic toward tumor cells by day 28.

This cytotoxicity

was the same v/hether or not the mice had been treated with
PKA.
To determine whether in vivo PHA treatment could modify
the cytotoxic action of BCG-activated macrophages on tumor
cells, mice were injected at various time intervals with PHA
either before or after BCG immuni.^ation.

Four groups of

mice,, containing 3 '-lice per group, were immunized with BCG
on day -l4.

L ice in ;'.roups 2, 3» and 4 were treated intra-

peritoneally with 400 ug of PM on day -15• day -9» or day -1
respectively.

Previous results (Table 2 & 3) have shovm that

this amount of PHA when given 1 day before tumor cell
challenge led to increased tumor development in treated mice,
lice in group 5 were a source of normal macrophages and
received no treatment.

Peritoneal exudate cells were

harvested and tested i or cytotoxicity on day zero.

Results

seen in Table 6 show thnt the in vivo treatment of mice with
PHA did not affect tlie response of theIr i^CG -activated
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TABLE 5
In Vitro Cytotoxicity of Macrophages from Tumor-Bearing i.iice
for Bl6 Tumor Cells
Source of Macrophages
Group

Treatment

Mean Number of Bl6 Tumor Cells/hpf
5

10

17

24

31

38

1.

none

l6.7

24.4

4$.8

36.2

33.9

32.8

2.

BI6 d 0

15.5

23.0

42.4

25.7* 29.9

32.0

3.

Bl6,d 0;PHA,d-l

1^.2

23-3 '^5.4

27.1^ 29.8

32.8

4.

PHA,(i-l

15.1

22.9

38.6

33.8

5.

BCG l4d before
aach tes^

7.1"

42.8

32.0

9.4* 18.5^ 14.6* 10.3* 12.5*

Indie, too a si^nificiint difference (p<.05) from control
group 1

Days

FIGURE 1
In Vitro Cytotoxicity of.Macrophages from Tumor-Bearing Mice
for Bl6 Tumor Cells
Source of Macrophages
Symbols:

A.

BOG l4 days prior to each test

B.

250 B16 cells, d 0

C.

250 BI6 cells, d 0; 400 ug PHA, d-1

D.

400 ug PHA, d-1
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TABLE 6
The Effect of _In Vivo PIIA Treatment on the Ability
of BCG-Activated iiacrophages
to Kill B16 Tumor Cells
Group

Treatment of Mice
Day-15

Day-DÏ

1.

—-

BOG

2.

PilA

iiCG

Da y-9

Tumor Cells/hpf
(mean + SD)

%
cytotoxicity

Day-1

————

11.1 jr

6,2

6^^

10.6 4]

6«2

ùo^/o

3.

BCG

VtUi

—

9.6+3.8

70%

4.

BOG

—

PHA

9.4+3.0

70'/$

———

—

——

31.6 + 10.3"'^

5»

—

O/o

Indicates a significant difference (p^.05) from control group 1
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macropi.a-es tovard tumor cells at tiie concentrations or timing
of treatments tested.
Spleen Cell and Lymphocyte Cytotoxicity Tests,
Three spleens, obtained fro id mice at 5 or-, y day intervals
following tiie injection of tumor cells, were pooled for
cytotoxicity testiric .

hi,'-:h yield lymphocytes suspensions

were prepared by cencriiugation of a portion of the spleen
cells in a Ficoll" itypaque gradient (see Table 1).

Lymphocytes

were tested in cytotoxicity assays to determine the effect of
PM treatment on lymphocyte cytotoxicity toward tumor cells
(Table 7 and Figure 2).

These results show a significant

difference on day 10 between the reponse of the

lymphocytes

from tumor-bearin;;; mice and the lymphocytes from tumorbearing mice which had been treated with PM.

Lymphocytes

from tumor-bearing: mice treated with PliA appeared to enhance
tumor cell growth on day 10, while those from mice not
treated with ï'hA were cytotoxic toward tumor cells.
A portion of the spleen cells were prepared by lysis of
contaminating, erythrocytes with ammonium chloride,

by tliis

technique both macrophages and lymphocytes could be
recovered (see Table l).

Cytotoxicity tests employing this

spleen cell preparation were performed to determine the
effect of an increased inacropha^re population on cytotoxicity
results.

The data In Table '6 and Figure 3 show similar

results to xhe lymphocyte cytotoxicity assay.

Spleen cell

cytotoxicity toward tumor cells was depressed in PILA.-treated
tumor-bearing mice on day 10 compared to tumor-bearing mice
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TABl# 7
In Vitro Cytotoxicity of Lymphocytes from Tumor-bearing Mice
for Bl6 Tumor Cells
Source of
Lymphocytes
Group

ivlf3c n number tumor colonies/well
10

17

24

31

38

21.9

29.1

38.9

30.0

14.7

4.2$

7.6* 17.2* 35.9

18.8

PHA, d-1

21.6* 39.0$

7.4* 25.4* 27.8

20,4*

PHA, d-1

23.8* 32.0* 33.9

Treatment

9

1.

none

31.9

2.

Bl6, d 0

20.1*

3.

Bl6, d 0

4.

42.0

32.9

Days

14.0

Indicates a significant difference (p<.05) from control
group 1
+

Indicates a significant difference (p<'.05) between test
groups 2 and 3

FIGURE 2

In Vitro Cytotoxicity of lymphocyte from Tumor-bearing Mice
for Bl6 Tumor Cells
Source of Lymphocytes
Symbols:

A.

250 Bl6 cells, d 0

B.

250 B16 cells, d 0; 400 up PHA d-1

C.

400 ug P1IÀ, d-1
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not treated with PHA,

No synergistic effects between

macrophages and lymphocytes were indicated by tliese results.
Macrophage Contamination of Lymphocyte Preparations
To determine whether part of the effects observed in
the lymphocyte cytotoxicity tests could be attributed to
contaminating macrophages, a cytotoxicity test was performed
using as effector cells macrophages which contaminated the
lymphocyte cell preparations.

Each Ficoll-Hypaque cell

suspension prepared for lymphocyte cytotoxicity testing was
tested also for the effects of contaminating macrophages.
These results are seen in Figure 4 and show that the
macrophages present in the Ficoll-Hypaque lymphocyte
preparations did not contribute significantly to the results
of the lymphocyte cytotoxicity assay.

No values were

obtained v/liich differed significantly from zero.
Serum Blocking Factors
Serum was collected and pooled from 3 inice in each
group at intervals of 5 or 7 days following tumor cell
injection and tested for the presence of serum blocking
factors.

Lymphocytes obtained from tumor-bearing mice, I8

dyas following the intraperitoneal injection of 250 tumor
cells, were used as effector lymphocytes.

To demonstrate

their cytotoxicity toward tumor cells, these lymphocytes
were compared to lymphocytes obtained from normal mice for
tlie expression of cytotoxicity in the presence of normal
seruiii.

All scrum sn:.iples were tosteu for the presence of

blocking factors by adding a portion of the test seruia to
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TABLE 8
In Vitro Cytotoxicity of Spleen Cells from Tumor-bearing Mice
i'or Bl6 Tumor Cells
Source of
Spleen Cells
Group

Treatment

bean nuiaber tumor colonies/well
5

10

17

24

31

38

45.0

45.2

1.

none

43.0

38.4

35.5

27.1

2.

Bl6,d 0

37.3

17.9Ï 14.9" 22.2* 40.6

34.5

3.

-il6, d 0
PllA, d-1

40.2

58.4* 16.5" 31.0* 53.1

43.3%

PHA, d-1

37.1

51.0* 50.3

24.7

4.

47.8

44.3

Days

Indicates a significant difference (p-^..05) from control
grou]j 1
+

Indicates a si.roiifleant difference (p<.05) between test
groirps ?, and 3

FIGURE 3
In Vitro Cytotoxicity of Spleen Cells from Tumor-bearing Kice
for Bl6 Tumor Cells
SolII'ce of Spleen Cells
Symbols:

A.

2'jU bio cells, d 0

B.

250 BI6 cells, d 0; 400ug PHA, d-1

C.

400ug PHA, d-1
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lymphocyte cytotoxicity tests.

ïlie results of tests for

serurt, blocking factors are summari..;ed in Table 9 and Figure 5SeruiL obtained from tumor-bearing; mice was capable of
blocking the in vItro killing of tumor cells by cytotoxic
l.y(iiphoo""tes.

The presence of serum blocking factors

initinlly ini;re:i sed as tumor grov/tli pro;;*;i-esi;ed and then
declined.

These changes were similar v.',iet:ier or not the

tu.Tior-bear i.n,

in Lee uad been first treated with FHA.

THU UFFUCT OF PHA Oi-i Ikl.iUNii hhSPUhbES
Antibody Production to Sheep Red blood Cells
The effects of PhA tre.tment on the antibody response of
mice to sheep red blood cells are su>..iiiarized in Table 10.
Four [groups of mice, containing 5 I'lice per ^'.rou,;, were
employed in this testing;,

bice in groups 1 - 3 were immunized

inti-aperitoneally with 2 X 10^ sheep red blood cells.

Iviice

in group 2 received a sin.:'1 e injection of 400 ug of PHA
intraperitoneally 24 hr prior to antigen, while those in
grouo 3 received tue sa.je amount of Pi Li 24 hr r f ter the
blood cells,

animals in group 4 received no treotment.

Six

days after the immunizing dose, all mice were bled, and
individual hemagglutinin titers were determined.

The prior

tx-eat.-ion t (if :! i ce v/ith PiLi caused a signii lean b reduction in
their antibody response to sheep red blood cells.
Delayed Hypersensi tIvity to BOG
bCG-imiiiUilized mice were tr'eated with various concen
trât ions of iiiA to deteriii i ne the effec b of treatn.enL on- the
expression of delayed h.y pers insiti v i ty.

i .ice wei e immunized
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TABLE 9
blockade of Lyiiiphocyte-i.^ediated Cytotoxicity by Seruiu Factors
froKi Tuhior-beari.nr i>iice
Source; of
Spleen Cells
Tumor bearing
Normal

Source of
Sei'um

Tumor colonies/well
(mean + SD)

Normal
Normal

Tumor
Stimulatio:

17.7 + 5.1
27.0
5.7*

52.5#

Tumor bearing D 5 Bl6
Tumor bearing
Bl6,PHA
Tumor bearing
PHA

14.5 + 6.6
22.7 + 4.6
19.3 ± 5.0

28.2#
9.0#

Tumor bearing D 10 Bl6
Tumor bearing
Bl6,PHA
PHA
Tumor bearing

23.1 2 5.5
25.8 + 4.2-"24.8 ± 2.4-

30.5#
45.8#
40.1#

Tumor bearing D 17 1316
Tumor bearin;
B16,PHA
PliA
Tumor bearing

23.4 ± 3.3'
26.8 + 4.926.0 + 3-3^

32.2#
51.4#
32.3#

Tumor bearing D 24 Bl6
Tumor bearing
B16,PHA
Tumor bearing
PHA

30.9 + 3.8*
32.8 + 6.2*
26.0 + 3.3*

74.1#
85.3#
46.3#

Tumor bearing D 31 Bl6
Tumor bearing
B16,PHA
Tumor bearing
PHA

28.3 + 4.0*
26.6
4.0*
24.0 ± 4.2*

59.9#
58.3#
35.6#

Tumor be 21 r ing D 3» Bl6
Tumor bearing
Bl6,PHA
Tumor bearing
PHA

20.7 + 4. 8
22.5 + 6.6
16.4 + 2.7

16.9#
27.1#

10.0#

7.3#

+

Treatment of mice:

Bl6 = 250 Bl6 cells, d 0
PHA = 400u^ VhA, d-1

••

Indicates a si^ni ficant diffei-ence (p<.05) from control %Toup
(line 1)
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TABLE 10
The Effect of PHA on Mouse Antibody Production
to Sheet) Red iilood Cells
Group

Treatment

Mice/group

Mean Antibody Titer
(Geometric mean ± SD)

1.

SRBC, d 0

5

5.6 ± 0.8

2.

SRBC, d 0
PM, d-1

5

3.8 + 0.3

.0l6

SRBC, d 0
PliA, d-i-1

5

5.0 + 0

.075

none

5

2.8 + 0.8

.008

3.
4.
a.

Level of significance of difference between test group and
control /rroup 1

v/ith BCG on day-14 followed by Footpad testing on day zero.
Nice in groups 2 - 4 were treated v/ith a single intra
peritoneal injection of 400 ug of PHA either 1, 2, or 3 days
prior to footpad testing.

Animals in group 5 were treated

for 3 consecutive days by injection of 400 ug of PHA per
day followed by footpad testing on the fourth day.

The

effects of PHA treatment on tlie expression of delayed
hypersInsitivity of BCG are summarized in Table 11.

Mice

in group 5i which had received 3 consecutive daily injections
of PHA, showed the greatest reduction in their inflammatory
response to BCG challenge.
To determine v/iiether PIIA treatment of BCG-sensitized
mice could abolish the ability of tiieir sensitized
lymphocytes to transfer BCG sensitivity to normal mice,
lymphocyte transfer experiments were performed.

Donor mice

were immunized with BCG on day -14, and transfer of spleen
cells v/ere performed on day zero.

Recipient mice in group 2

and donor mice in jrroup 3 were treated v/ith 400 ug of PHA
daily for 3 consecutive days followed by lymphocyte transer
on the fourt i day.

The effect of the transfer of normal

lymphocytes into normal recipients v;as also tested in group 5»
Table 12 shows that tlie administration of PHA for 3
consecutive days efft.ctively blocked the ability of BCGsensi tized iymj)hocytes to transfer sensitivity to normal
mice.

Treatment of recipient mice v/ith PHA did not abolish

the transfer of BCG sensitivity y/ith sensitized lymphocytes.
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TABLE 11
The Effect of PHA on tlie Delayed Hypersensitivity Response of
la ice to BCG Proto'olasm
Group

Treatment

Mice/group

Increase in foot
pad thickness (mm)
(mean + SD)

1.

BCG, d-l4

5

0.55 + .17

——— —

2.

BCG, d-l4
FllA, d-1

5

0.38

.13

.041

BCG, d-l4
PHA, d-2

5

0.40

.12

.123

BCG, d-l4
PH.:t , d-3

5

0.48 + .12

.242

iiCG, d-l4
PHA, d—1,—/%-3

5

U.12 jr .OB

.002

none

5

0.18 + .13

.002

3.
k.
r_

6.

a.

Level of significance of difference between te^t A-roup
and control ^:;;roun 1.

5?

TABLE 12
The Effect of Pi IA Treatment on Passive Transfer of BCG
Imrriuni-ty v/ltli Sensitized Lytaphocyt es
Group

bice/^roup
Donor

Treri tment
Recipient

Increase in foot
pad thickness (mm)
(mean + SD)

1.

10

BCG, d-l4

Normal

.28 + .13

2.

10

BCG, d — 14

PliA ,d-l,
-2,-3

.28 + .10

3.

10

PHA, d-1,-2,-3
BCG, d-l4

Normal

.15 ± .11*

4.

10

Normal

Normal

.16 ± .12*

Indicates a significant difference (p<.05) between test ^^roup
and control 6/roup 1.

CHAPTER 4

DISSCUSSION
THE EFFECT OF PHA ON THE lWi:UNE RESPONSE
The ability of PHA treatment to reduce trie survival time
of mice follov.'in:, tumor cell challenge v/hlch was demonstrated
in this study, was thought to result from the intraction of
this mitogen witli certain components of the immune system.
Based upon tlie evidence of the present study, it was
hypothesized that the action of PHA was upon lymphocyte
mediated cytotoxicity.

Lympliocytes exposed to P}[A were

rendered temporarily incapaole of reacting specifically
toward tumor cells.

In fact, a few days after PHA treatment,

lymphocytes stimulated tumor growtii in vitro.
The present studies have shown that, following tumor
cell challenge, treatment of mice with PHA both reduced
their survival time and increased the development of lung
metastases.

Apparently the treatment of mice with PHA

resulted in a suppression of the immune response, thus
allowing for more rapid tumor development.
In Vitro Cytotoxicity Assays
In oi'der to expia in the effects oi PHA treatment on the
iiiimune response of mice to tumor cells, different components
of the itoinune system were studied.

Because tumor immunity

was believed to be mediated by T-lymphocytes (2, l6, 46) and
macro] liages (12, 31» 49, 50), cytotoxicity tests employing
till,se tv/(i cell iiofnilu i, ions were pex- Pormed to iJîtori iine
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whether or not any differences existed between the cells of
tumor-bearing mice and the cells of tumor-bearinp, mice
treated with PllA.

Evidence has been presented which showed

that sera from tumor-beuring mice blocked the destruction of
tumor cells by immune lymphocytes (4$, 4?, 48).

These

huiaoral blockin.^ factors might have been antibody directed
against tumor antigens.

Because PHA has been shown at times

to enhance antibody production to antigens, sera from mice
were collected and tested for the presence of serum blocking
factors.
Results showed that the presence of serum blockingfactors was not significantly different between tumor-bearing
mice Vvhich had been treated with PM and untreated mice.
Interestingly, the mice ti-eated only with PHA also apparently
produced serum factors which could protect tumor cells from
immune lymphocytes.

The reasons for this were unclear

althougli, according to the theory of Kolb and Granger (62),
low concentrations of lymphokines could stimulate tumor cell
growth.

Low levels of circulating PHA-induced lymphokines

might produce a similar effect.

The phenomenon of immune

enhancement will be discussed more fully in a later section.
Tlie data also have shown that macrophages from PHA
treated tumor-be,ring mice and those from untreated tumorb ear in/': mice manifester equal cytotoxicity toward tumor cells.
No evidence was found from this study to indicate any
differences between these macrophage populations on their
ability to inhiliit tumor- cell grov/th.
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In vitro studies of tiie effect of PiiA treatment on the
expression of lymphocyte mediated cytotoxicity, revealed
that PHA-stimulated lymphocytes from both tumor-bearing and
tuiQor-free mice exiiibited some early cytotoxic effects
tovyard tumor cells.

However, lymphocytes from PHA-treated

tumor bearing mice later became refractory to antigenic
challenge and at 10 days were incapable of responding
specifically toward tumor cells.

Lymphocytes from untreated

tumor-bearing mice manifested cytotoxicity foi* tumor cells
through day 24, but cytotoxicity decreased rapidly thereafter.
This cytotoxicity appeared to represent the development of
specific tumor immunity which gradually disappeared as tumor
growth progressed.

A similar effect was reported by

riartholomaeus et al. (10) v/ho o served that lymphocytes
obtained from lymph nodes draining tumors became increasingly
more stimulatory as tumor growth progressed.
In an attempt to relate these iji vItro results to
in vivo observations, it was thought that during this PHAinduced refractory period v/hen a normal immune response should
be developing, tumor cell proliferation remained unchecked and
was one factor responsible for the early death observed in
Ph(A-treated tumor-bearing mice.

Results als-o indicated that

PHA-stimulated lymphocytes from both tumor-bearing and
tumor-Tree iiice, although initially cytotoxic, later
stimulated tumor cell proliferation _in vitro.
The results of the spleen cell sytotoxoicity assay
showed no si,,ni.ficant differences froia tiie lymphocyte

cytotoxicity assay,

apparently the increased percentage of

macrophages in the spleen cell preparations had no major
effects on the cytotoxic response.

However, on day 10 the

yield lymphocyte preparations gave slifihtly hi. h values for
both the inhibition and for the enhancement of tumor growth
than lid the spleen cell prepai-ations.

This may indicate that

the cells Ï,mediating these repsonses were lyrapocytes arid that
tue greatest responses were observed in the preparations with
a hi^h percentage of lywpliocytes.
From these studies it appeared that the effect of PHA
was upon lymphocyte mediated cytotoxicity.

First PH% delayed

the development of specific tumor immunity, possibly Hue'to
tlie inability of PHA-stimulated lymphocytes- to recognize or
to react specifi cailly with tumor cell antigens.

Secondly,

PHA-stimulated ly/nphocytes temporai'ily enhanced tumor cell
growth.
The Effect of PhA on T-Cell Mediated Immune Responses

Thé results of ti.e cytotoxicity assays suggested tiiat
T-lymphocy tes were af

cted by riiA ti e i tment and tnese cells

were temporarily incapable of specifically responding to
antigen,

To confirm this hypothesis, the effect of PHA on

otiier T-oell u.edj.j!tod functions also was investigated.
r ice treated with P jI a prior to anti ,,enio clinllenge with
s lie eu red bloc J cell.; , piuduced si gnif icantly less antibody
than did mice not treated with PHA.
between

tiio

i3-

and T-lym^liocy tes

wrs

Since cooperation

shown to

cducti un oi i-uit 1--siiotai rod blwod

lie

necessary for

i 1 li n L U'O-1 i os (20, 21),
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the reduction in ant:i - sheep red blood cell titers;, observed
in this and other, studies following PHA treatment, could
result from the inability of T-lymphocytes to respond
effectively to the antigen.

However, anitgen processing by

macrophages or even a direct effect u^on B-lympliocytes might
also be involved.
The expression of delayed hypersensitivity to BOG was
examined also.

I'he treatment of BCG-sensitized mice with

PHA reduced significantly the delayed hypersensitivity response
to challenge v/ith BGG protoplasm.

Lymphocytes obtained from

BCG-sensitized donors which had been treated with PHA failed
to transfer BGG sensitivity to normal unirnmunized recipients,
v/hile lympiiocytes fro . untreated BCG-sensitized donors were
effective in this capacity.
Vv 'liich

Since only donor lymphocytes

had been exposed to PiiA failed to transfer sensitivity,

the action of PHA appeared to be upon donor lymphocytes,
rendering them unresponsive to the antigen.

The fact t;at

macrophages were unaffooted by this treatment was shown by this
transfer of BCG-sensitized lymphocytes into uniuimunixed
recipients which had Ijeen previously treated with the same
dose of PHA.

In this case only the recipient's macrophages

had been exposed to PHA while the donor's sensitized lymphocytes
had not.

Following oliallenge with BOG protoplasm, a normal

inflan;,atory res )onse waa observed.

These results suppoi't

the view tiiat PHA-treated lymphocytes were less effective in
responding to antigens than were lymphocytes which had not
boon ex nosed

to Pi .
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CCI PARI JUL OF iîLJULTS TO OTHER RELATED STUDIES
ilariy studies have demonstrated that lymphocytes treated
in vitro with PHA were capable of either killin<^ tumor cells
directly or of releasing, soluble mediators v/hich destroyed
tumor cells (13. 40, 51-5^^-).

Other studies iiave shown that

stimulât!on of the immune system with agents such as BOG
(9, 11) or Toxo'ola sua

) resulted in nonspecific killing

of tumor cells, ponsibly mediated thorugh the release of
lymphokines from sensitized lymphocytes.

By analogy, it

m in;ht appear that PHA would be similarly beneficial in
treating malignancies, however, the present studies iiave not
supported this view.

In contrast, the ijQ vivo effects of

PHA treatiiient on tumor .^I'owth appeared distinctly different
from the in vitro effects.
Otiier investigators, however, have presented evidence
wliich suggested that jji vivo PHA treatment could result in a
significant anti-neoplastic effect (72, 90).

Robinson and

l.ekori (90) have claimed that PHA "modified" lyinphocytes
were capable of kill in- tumor cells _in vivo.

In tlieir study

mice were treated with P}{A prior to the injection of ascites
tumor cells, and 7 days later the tumor volume was determined.
When ] HA wns administered 72 lir prior to tum.or cell
challenge, decreased numbers of tumor cells were found on
day 7 coLipared to controls not treated v.ith PHA.

However,

when PHA was given 120 hr prior to tumor cell challenge, an
increased tumor load was present on day 7»

Nevertheless,
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"based on these reults, the tentative use of PHA in cancer
patients was atte:npted, and some temporary improvement was
reported (88, 89).
For an explanation of the results of Robinson and
Helcori (90) to be consistent with the data presented in this
study, it must take into account both the sequence and timing
of changes occuring in lymphocyte populations stimulated
with PHA.

The first clian^ie observed in this study, apparent

5 days after PH4 treati.ient, was the expression of lymphocyte
mediated cytotoxicity toward BI6 tumor cells.

This finding

was consistent with the observations of others that lymphocytes
treated _in vitro with FM could destroy tumor cells.

It is

not surprising, therefore, that mice given PHA 72 hr prior to
tumor cell challenge had reduced tumor volumes (90).

Tlie

second change observed in this study appeared after 10 days
and v;as that PIIA-stimul :i ted lymphocytes failed to respond
specifically toward tumor cell antigens and actually stimu
lated _in vitro tumor cell proliferation.

Lymphocytes from

untreated tuiiior-bearing mipe remained cytotoxic toward tumor
cells at this time.

Therefore, the increased tumor volume

observed by Robinson and Wekori (90) in mice treated with
PM 120 hr prior to tumor cell challenge, indicated that the
Lntitial cytotoxic response of the lymphocytes was largely
gone by this time ad indicated also an inability of lympho
cytes to develop a specific immune response.
Il obley et al. (72) also showed a slightly increased
survi val time in PHA-tre:ited mi ce over normal mi ce following
tlie Injection of ascites carcinoma.

Horinal luice survived on
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the ayeiTi-'-.e ni" lens th.'ni 8 days while PHA-treated mice
survived for 10 days.

Because of this relatively short

survival time, it is doubtful that à specific response could,
have effectively developed to control tumor grov/th.

There

fore, the early cytotoxic effects of PHA-treated lymphocytes
mi.frht have played a role in prolon,'in;' survival, while cellmediated ii.'iiuunity was not a critical factor.
Uesprite trie initial cytotoxic response of lymphocytes
to PHA, the direct injection of PHA into cancer patients does
not appear warranted based upon observations of the present
study.

The use of other nonspecific stimulants of the immune

system, such as BOG, in combating malignancies have proven
effective in many cases (9, ll).

The action of this agent

might be to stimulate specifically reactive lymphocytes to
produce lymphokines which act either directly upon tumor
cells or activate macrophages to kill tumor cells.

Although

the initial effects of BGG upon lymphocytes were immunologlcally specific, tiie resulting destruction of tumor cells
was probably noiis^^eci Tic (9).

In contrast, while the

initial action of PHA might be to promote some nonspecific
tumor cytotoxicity, it might also block temporarily the
development of specific tuinor immunity.

One difference in

the effect of BCG and PHA on tumor development might be due
to the bloclcafce of specific tumor immunity by systemic PliA
treatment.
One possible means of avoiding the blockage of specific
tumor .immunity while still allowing for the production of
PiL;-induced cytotoxic lymphocytes would be to treat lympho
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cytes

vitro with UlA and to reinject them into autologous

hosts.

Cheems and Hersh (19) reported that exposure of

lymphocytes to PHÀ in vitro prior to injecting the stimulated
cells into subcutaneous tumor nodules, resulted in a signif
icant anti-neoplastic effect with complete or partial
ref^ression in 2? out of 29 nodules.

Frenster and Rogoway (3^)

also were successful in inducing regression of pulmonary
metastases in cnncer patients in intravenous injections of
autologous lymphocytes treated jji vitro with P?[A.

Immune Enhancement of Tumor Growth
The results of the lymphocyte cytotoxicity tests have
siiown that lymphocytes from PHA-treated mice at times could
enhance tumor cell growth.

Similarly lymphocytes from mice

with far advanced tumors also appeared to be somewhat stim
ulatory toward tumor growth.
occur

Possibly similar effects also

V i.vo and may be a contributing factor to the

shortened survival time of PHA-treated tumor-bear in;-, mice.
Pirt of the stimulatory effects of PHA- stimulated lymphocytes
on tujiior :-I'owth In > dee may be due to the phenomenon of
immuen enhancement.

Prehn (8l, 82) and Prehn and Lappe (63)

have advanced the theory that weak immune responses may
stimulate tumor cell ^..rowth.

The concept that lympheoytnr:

'û;;ht serve as a source of essential growth factors was first
proposed by Carrel (I?) In 1922.

Carrel observed tliat

secretory products of lymphocytes increased the proliferation
of fibroblasts j_n vitro.

Kolb and Granger (62) have presented

ev i den ce whl ch uu; gujtud that lymphoto^-iiii. may uo the
secretory product res,

ble for tu.r et cell proliferation.

67

Lov/ concentra lions ci' lyiaphotoxin stimulated target cell
growth while high concentrations were inhibitory.

Fidler (32)

observed tliat the mixture of small numbers of sensitized
lymphocytes with tumor cells led to increased _in vitro tumor
cell proliferation v/hi le lar. e numbers of sinsitized
lymphocytes inliibltod tumor cell grov/tii.

Whether soluble

mediators, such as lymphotoxin, or direct cell-to-cell
contact was necessary for im une enhancement still remains
unknown.
Investigations by others have shown that stimulation of
lymphocytes with PJIÀ caused a release of lympnokines and
subsequent cell division.

Based upon the observations of

Fidler (32) and Kolb and Granger (62), the immune enhancement
theory would rpedict that as the number of PHA-responding
lymphocytes decreased or as the lympliokine production
decreased, an initially cytotoxic immune response would
later become an immune enhancing response.

The lymphocyte

cytotoxicity tests performed in this study support tiiis
assumtTion.

Lymphocytes from fHA-treated mice were at first

slightly cytotoxic tov/ard tumor cell growth on day 5 but
stimulated tumor cell growth on day 10.

Anaclerio et al. (4)

examined the effect of m vivo concanavalin A administration
on the develo irieint i.i spleen cell cytotoxicity.

Spleen cells

manifested the groa.tesfc cytotoxicity 24 hr after the
intravenous injection of tlie mitogen and declined thereafter.
On the other hand, Fidler (32) found that the ^ vitro
incubation of lymphocytes for 4 days with concanavalin A
resulted iri t lelr stimulatipn of tumor cull

rov/t;i when tested
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on dsy 5.

Possibly a strong early response of lymphocytes

to T-cell mitogens resulted in the development of cytotoxic
lymphocytes, while a declining response produced enhancing
lymphocytes.
Lymphocytes taken from mice which carried tumors for
more than 30 days snowed a slight enhancing effect
on tumor cell growth.

vitro

A similar effect was reported by

Bartholamaeus et al. (10).

They 0 .served tnat lymphocytes

obtained from the lyîiiph nodes draining tumors because
Increasingly more stiiuulatroy as tumor growth progressed.
Whether observations of the present study were related to the
phenomenon of immune enhancement is not known.

However, as

tumor growth progressed, the ratio of effector cells to
tumor cells is necessearily decreased.

Conceivably, this

could result, at some point, in immune stimulation.

There

fore, in those mice in which tumors grow fastest, lymphocyte
enhancement of tumor growth would be expected to develop
first.

Because of tlie early enhancement of tumor growth in

mice treated with PHA, tumor growth would be accelerated
compared to untreated mice, and lymphocyte enhancement should
be first observable in this group.

In fact, during the latter

stages of the lymphocyte cytotoxicity tests, lymphocytes from
PHA-treeted tumor-bearing appeared to be slightly more
stimulatory towai'd tuinor cell grov/th than were lymphocytes
from tumor-bearing mice.
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PROPOSED hODWL POii I'ilii ACTION OFPHA ON THiS. IkMUNE RESPONSE
Although PiiA has been reported by some workers to
enhance antibody production (36, 97), other investigators have
reported a suppression of both antibody production (lO, 24, 30»
38, 57) and tlie development of cell-mediated iiaiaune responses

(70, 100, 102).

The theories which have been offered to

account for these suppressive effect include, 1) the trans
formation of imnuno-coropetent cells into blast cells which
were inc-pable of responding to antigenic challenge (99),

2) the preferential stimulation of a suppressor T-cell
population capable of blocking antibody production by B-cells
(84),

3) the blockage of draining blood vessels causing re

tention of the antigen at the site of injection (30),
4) the activation of macrophages resulting in the destruction
of antigens (56), or 5) a depression in phagocytic activity
which rediced antigen processing (66).

Although other

mechanisms also might be involved, the present studies support
tiie view that PhA-stimulated lymphocytes were temporarily
incapable of reacting specifically with tumor cell antigens
and were, therefore, retarded in the development of specific
tumor immunity.
An understanding of the sequence of changes occuring in
PlL'i-stlmu.lcited ly u -hocytes is necessary to explain the effect
of PKA on immune systems.

The development of lymphocyte

mediated cytotoxicity toward tumor cells was the first
lymphocyte response observed in this study.

This initial

cytotoxicity vv;ru: temporary and was later replaced by

lymphocyte eniianceiaent of tumor cell f'.rowtii.

At this time

lymphocytes from untreated tumor-bearing mice remained
cytotoxic toward tumor cells.

The next change to occur in

PHA-stimulated lymphocytes from tumor-bearing mice was a
complete recovery of iiamune competency and the expression of
cytotoxicity equal to that expressed by lymphocytes from
untreated tumor-bearing ,,iice.

however, tuiaor development

would be fartlier advanced in PHA-treated mice than in
untreated mice, and the increased tumor load would shorten
their survival time despite the recovery of their lymphocytes

CHAPTER 5
SUMMARY

The effects of PM treatment in mice on the development
of specific tumor immunity and the subsequent effect on
tumor growth w.s investigated.

Results have shown that

treatment of mice with PHA resulted in decreased survival
times following intiaperitoneal tumor cell challenge.

It was

further shown that treatment of mice with PHA resulted in an
increased number of lunr, metastases following intravenous
challenge with tumor cells.

Because of these apparently

immunosuppressive effects of PHA on the development of tumor
immunity, various in vitro cytotoxicity assays were performed
to discover the specific effects of PHA on the immune system.
i ta cru 'ha,; e cytotoxicity tests revealed no differences
between macrophages from tumor-bearing mice which had been
treated with PHA and the macrophages from untreated tumorbearing', mice.
Assays _'.or t.-ie ui ^scnce of aerui;i blocking, factors
similarly revealed no significant differences between tumorbearing mice and tumor-bearing mice treated with PHA,
The evidence from this study has indicated that the
pivliic Lfile effect of PUA was upon lymphj jjt....

lymphocyte

cy to tori ci ty tests indicated that lyiiphocy tes from tumorbearing ifiice treated \/ith PHA were delayed in the development
of a specific immune response as compared to untreated
tumor-beriri.ng mice.

To determine whetlier other T-cell

11:0 j i : led j'u/a i. iiiia wore also a iVeatrd , v PHa l;i-e;<tiiient, other
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tests were perfunned.

Results inâica led that treatment of

mice with FHA significantly reduced their antibody resyonse
to sheep red blood cells when the PHA was given prior to the
antigen.

It v/as found also that the treatment of BGG-

imiiiunized mice with PiiA not only reduced their skin reaction
to clir-llenfe v/it.hi tiCG protoplasm, but also abolished the
ability of their sinsitized lymphocytes to transfer immunity
to normal mice.
The action of

, however, did not appear to be limited

solely to the delay in the development of tumor immunity/.
These results have indic:,ted that PM-stimulated lymphocytes,
w Li le temporarily cytotoxic, later stimulated tumor cell
proliferation

vitro andm therefore, may also have

accelerated tux.or growth in WIA-treated mice.

Present theories

for file immune stimulation of tumor growth include, the
presence of low concentrations of lymphocyte secretions, such
as lymphotoxin, capable of stimulating tumor cell growth, or
low ratios of effector cells to tumor cells also canaille of
causin': increased tumor cell growth.

Neither theory is

mutually exclusive, and both actually may he stating the same
princ i.ple.
AltliOUfrh alternative theories have been proposed to
explain the iininunosuppressive effects oi Plia, from these
studies it ;-jppeared tu t tlie effect of Pha was upon lymphocytemediated cytotoxicity.

PhA apparently had a dual effect upon

the iiimune response of lymphocytes to tumor cells.

First PHA

delayed the develoj>ment oi specific tuiuor ii;i;i.unity, possibly

due to the inability of stimulated lymphocytes to react
specifically with antigens, and secondly, PHA-stimulated
lymphocytes temporarily enhanced tumor cell growth.
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